41587 Comparing Clinical Trial Drug Efficacy of Biologics for Atopic Dermatitis by Patient Level Characteristics

Introduction: Biologic therapies such as JAK-inhibitors (Abrocitinib, Upadicitinib), IL-4 (Tralokinumab), and IL-13 (Dupilumab) antagonists have recently been approved by the FDA for moderate-to-severe atopic dermatitis (AD). Given these advances and limited understanding of the comparative drug efficacy, we sought to summarize and evaluate drug efficacy, safety, and monitoring requirements by patient profile to optimize outcomes.